Sign inJoin free

Watch / Global Markets

The robot revolution and how to invest in it

28 Apr 20267:21

The robot revolution and how to invest in it

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key points:

  • Industrial robotics orders rising at FANUC and Keyence, especially from the US and China

  • Intuitive Surgical’s da Vinci platform seeing strong procedure growth and higher tool usage

  • Walsh sees robotics adoption at a potential tipping point across factories and hospitals

David Walsh from Sarto Advisory outlines what he sees as a structural acceleration in real‑world robotics, driven by both industrial demand and advances in artificial intelligence. Walsh points to Japanese giant FANUC, which he notes has upgraded its outlook on the back of stronger robotics orders, particularly in medium to heavy industrial applications such as auto and tech manufacturing. He highlights rising demand from the United States, which he views as evidence of reshoring and a manufacturing “renaissance”, and is surprised by improving orders from China, which he interprets as a potential trough in Chinese industrial investment.

Walsh also cites another Japanese leader, Keyence, which he describes as focused on vision systems and sensors with high margins and strong US order books. He regards this as corroboration of the upturn in industrial robotics demand, even though the company remains guarded in its formal guidance.

In healthcare, Walsh focuses on Intuitive Surgical (NASDAQ:ISRG) and its da Vinci systems, now exceeding 11,000 installed robots by his count, with procedures growing in the mid-teens. He argues the economics work for surgeons, patients and hospitals, and notes heavy R&D spend and AI integration. He acknowledges concerns around GLP‑1 impacts on bariatric procedures and tariff exposure, but still sees expanding applications and margin growth.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy